Girinsky T, Lubin R, Pignon J P, Chavaudra N, Gazeau J, Dubray B, Cosset J M, Socie G, Fertil B
Department of Radiotherapy, Unité Inserm 247, Hôpital Pitié Salpétrière, Paris, France.
Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):3-7. doi: 10.1016/0360-3016(93)90137-k.
To determine whether in vitro radiosensitivity parameters are predictive of treatment outcome.
Biopsies were obtained from patients with head and neck cancers (57) and cervical carcinomas (20) and in vitro radiosensitivity parameters were obtained using the CAM plate assay.
In most cases (75%) patients were treated with radiation alone. The median follow up was 461 days. When the whole group of head and neck cancers and cervical carcinomas was considered, patients with a SF2 value below 0.36 had a higher 2-year local control rate (93% versus 68%) and a higher 2-year survival rate (71% vs. 62%) than those with SF2 values above that threshold, but differences were not significant. These trends persisted when head and neck cancers were considered alone with a higher local control rate (86% vs. 67%) and a higher survival rate (75% vs. 52.5%) obtained for patients with a SF2 value below 0.36. When the alpha value was evaluated for the whole group of patients a significantly higher local control rate (80.5% vs. 40.5%) and overall survival rate (71% versus 37.5%) at 2 years were obtained for patients with alpha values above 0.07 Gy-1. When only the group of head and neck cancers was considered, local control rate was significantly higher (79% vs. 33%) but overall survival rate (65.5% vs. 33%) was not significantly higher for alpha values above 0.07 Gy-1.
These results are encouraging but need to be confirmed with a larger number of patients with a longer follow-up.
确定体外放射敏感性参数是否可预测治疗结果。
从头颈癌患者（57例）和宫颈癌患者（20例）获取活检样本，并使用克隆形成平板试验获得体外放射敏感性参数。
在大多数病例（75%）中，患者仅接受放射治疗。中位随访时间为461天。当将头颈癌和宫颈癌的整个组考虑在内时，SF2值低于0.36的患者2年局部控制率（93%对68%）和2年生存率（71%对62%）高于SF2值高于该阈值的患者，但差异不显著。当单独考虑头颈癌时，这些趋势仍然存在，SF2值低于0.36的患者获得了更高的局部控制率（86%对67%）和更高的生存率（75%对52.5%）。当对整个患者组评估α值时，α值高于0.07 Gy-1的患者在2年时获得了显著更高的局部控制率（80.5%对40.5%）和总生存率（71%对37.5%）。当仅考虑头颈癌组时，α值高于0.07 Gy-1的患者局部控制率显著更高（79%对33%），但总生存率（65.5%对33%）没有显著更高。
这些结果令人鼓舞，但需要更多患者进行更长时间的随访来证实。
